A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019)
A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)
Sven J. van der Lee (Vrije Universiteit Amsterdam)
Erik van den Akker (Leiden University Medical Center, TU Delft - Pattern Recognition and Bioinformatics, Molecular Epidemiology)
Najada Stringa (Amsterdam UMC)
Marc Hulsman (Vrije Universiteit Amsterdam, TU Delft - Pattern Recognition and Bioinformatics)
Niccolo Tesi (TU Delft - Pattern Recognition and Bioinformatics, Vrije Universiteit Amsterdam)
P. Alexopoulos
G. Rossi
J. van der Zee
Marcel J.T. Reinders (TU Delft - Pattern Recognition and Bioinformatics, Delft Bioinformatics Lab)
undefined More Authors (External organisation)
More Info
expand_more
Abstract
The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.